| Advanced small cell lung cancer (SCLC): new challenges and new expectations N Tsoukalas, E Aravantinou-Fatorou, P Baxevanos, M Tolia, K Tsapakidis, ... Annals of translational medicine 6 (8), 2018 | 94 | 2018 |
| Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau? P Baxevanos, G Mountzios Annals of translational medicine 6 (8), 2018 | 66 | 2018 |
| PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer N Tsoukalas, M Kiakou, K Tsapakidis, M Tolia, E Aravantinou-Fatorou, ... J buon 24 (3), 883-888, 2019 | 58 | 2019 |
| Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1≥ 50% who … G Metro, A Addeo, D Signorelli, A Gili, P Economopoulou, F Roila, ... Journal of thoracic disease 11 (12), 4972, 2019 | 37 | 2019 |
| Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score≥ 50% treated with front-line pembrolizumab A Friedlaender, G Metro, D Signorelli, A Gili, P Economopoulou, F Roila, ... Acta Oncologica 59 (9), 1058-1063, 2020 | 34 | 2020 |
| Advances on systemic treatment for lung neuroendocrine neoplasms N Tsoukalas, P Baxevanos, E Aravantinou-Fatorou, M Tolia, ... Annals of translational medicine 6 (8), 2018 | 27 | 2018 |
| Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression≥ 50% G Metro, GL Banna, D Signorelli, A Gili, D Galetta, G Galli, ... Journal of Immunotherapy 43 (9), 299-306, 2020 | 22 | 2020 |
| Steroid use independently predicts for poor outcomes in patients with advanced NSCLC and high PD-L1 expression receiving first-line pembrolizumab monotherapy G Mountzios, A de Toma, P Economopoulou, A Friedlaender, M Banini, ... Clinical lung cancer 22 (2), e180-e192, 2021 | 18 | 2021 |
| Carcinoembryonic antigen and carbohydrate antigen 19-9 serum levels in non-small cell lung cancer N Tsoukalas, ID Kostakis, C Giaginis, M Tolia, M Galanopoulos, M Kiakou, ... J buon 22 (6), 1390-1394, 2017 | 13 | 2017 |
| Poor performance status and front-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients with PD-L1> 50%. A Addeo, G Metro, D Signorelli, P Economopoulou, F Roila, GL Banna, ... Journal of Clinical Oncology 38 (15_suppl), e21651-e21651, 2020 | 6 | 2020 |
| Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature N Tsoukalas, K Tsapakidis, M Tolia, M Kiakou, M Galanopoulos, ... Cancer Diagnosis & Prognosis 4 (2), 198, 2024 | 2 | 2024 |
| Engagement of patients with cancer with digital health platforms: An age-based analysis. PA Kosmidis, P Baxevanos, T Kosmidis Journal of Clinical Oncology 42 (16_suppl), e13671-e13671, 2024 | | 2024 |
| 142TiP SARC-Digital: An obServational, rAndomized, pRospeCtive study of the impact of digital health interventions on symptom and side-effect management in patients with … S Kokkali-Zervos, JD Moreno, A Kyriazoglou, V Georgoulias, ... ESMO Open 9, 2024 | | 2024 |
| Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller G Mountzios, A de Toma, P Economopoulou, A Friedlaender, M Banini, ... CLINICAL LUNG CANCER 22 (2), E180-E192, 2021 | | 2021 |
| Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score≥ 50line pembrolizumab. A Friedlaender, G Metro, D Signorelli, A Gili, P Economopoulou, F Roila, ... Acta Oncologica, 2020 | | 2020 |
| P-223 Prognostic role of inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy A Ioannou, S Demiri, G Papaxoinis, E Sarris, E Klouva, P Baxevanos, ... Annals of Oncology 31, S163, 2020 | | 2020 |
| Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest G Mountzios, D Signorelli, JR Cobo, M Banini, P Economopoulou, ... Annals of Oncology 30, v622-v623, 2019 | | 2019 |
| P1. 16-09 Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort G Metro, D Signorelli, J Rey-Cobo, M Banini, P Economopoulou, ... Journal of Thoracic Oncology 14 (10), S589, 2019 | | 2019 |
| 368 Primary breast carcinosarcoma N Tsoukalas, K Tsapakidis, E Aravantinou-Fatorou, P Baxevanos, M Tolia, ... International Journal of Gynecological Cancer 29 (Suppl 3), A152-A152, 2019 | | 2019 |
| Prognostic role white blood cell levels in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy A Ioannou, S Demiri, G Papaxoinis, V Rapti, E Klouva, E Sarris, ... Annals of Oncology 30, iv80, 2019 | | 2019 |
